Viraj Sanghvi

Dr. Viraj Sanghvi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
KSKamini Singh
Kamini Singh
JLJianan Lin
Jianan Lin
NLNicolas Lecomte
Nicolas Lecomte
PMPrathibha Mohan
Prathibha Mohan
AGAskan Gokce
Askan Gokce
HWHans-Guido Wendel
Hans-Guido Wendel
Pancreatic adenocarcinoma (PDAC) epitomizes a deadly cancer driven by abnormal KRAS signaling. Here, we show that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and that pharmacological inhibition of eIF4A has single-agent activity against murine and human PDAC models at safe dose levels. EIF4A was uniquely required for the translation of mRNAs with long and highly structured 5′ untranslated regions, including those with multiple G-quadruplex elements. Computational analyses identified these features in mRNAs encoding KRAS and key downstream molecules. Transcriptome-scale ribosome footprinting accurately identified eIF4A-dependent mRNAs in PDAC, including critical KRAS signaling molecules such as PI3K, RALA, RAC2, MET, MYC, and YAP1. These findings contrast with a recent study that relied on an older method, polysome fractionation, and implicated redox-related genes as eIF4A clients. Together, our findings highlight the power of ribosome footprinting in conjunction with deep RNA sequencing in accurately decoding translational control mechanisms and define the therapeutic mechanism of eIF4A inhibitors in PDAC.Significance: These findings document the coordinate, eIF4A-dependent translation of RAS-related oncogenic signaling molecules and demonstrate therapeutic efficacy of eIF4A blockade in pancreatic adenocarcinoma.

5 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VSViraj Sanghvi
Viraj Sanghvi
PMPrathibha Mohan
Prathibha Mohan
KSKamini Singh
Kamini Singh
LCLinlin Cao
Linlin Cao
MBMarjan Berishaj
Marjan Berishaj
HWHans-Guido Wendel
Hans-Guido Wendel
Inhibition of the eIF4A RNA helicase with silvestrol and related compounds is emerging as a powerful anti-cancer strategy. We find that a synthetic silvestrol analogue (CR-1-31 B) has nanomolar activity across many cancer cell lines. It is especially active against aggressive MYC+/BCL2+ B cell lymphomas and this likely reflects the eIF4A-dependent translation of both MYC and BCL2. We performed a genome-wide CRISPR/Cas9 screen and identified mechanisms of resistance to this new class of therapeutics. We identify three negative NRF2 regulators (KEAP1, CUL3, CAND1) whose inactivation is sufficient to cause CR1-31-B resistance. NRF2 is known to alter the oxidation state of translation factors and cause a broad increase in protein production. We find that NRF2 activation particularly increases the translation of some eIF4A-dependent mRNAs and restores MYC and BCL2 production. We know that NRF2 functions depend on removal of sugar adducts by the frutosamine-3-kinase (FN3K). Accordingly, loss of FN3K results in NRF2 hyper-glycation and inactivation and resensitizes cancer cells to eIF4A inhibition. Together, our findings implicate NRF2 in the translation of eIF4A-dependent mRNAs and point to FN3K inhibition as a new strategy to block NRF2 functions in cancer.

2 July 2012 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
VSViraj Sanghvi
Viraj Sanghvi
LSLaura F. Steel
Laura F. Steel

15 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MZMinggang Zhang
Minggang Zhang
ZZZeguo Zhao
Zeguo Zhao
YPYuri Pritykin
Yuri Pritykin
MHMargaret Hannum
Margaret Hannum
ASAndrew C. Scott
Andrew C. Scott
MHMorgan Huse
Morgan Huse
Up-regulation of the miR-200c–EpCAM axis promotes the engraftment, persistence, and antitumor activity of transferred T cells in murine models.

1 January 2011 in Virus Research
Verified
Journal Article
Closed access
VSViraj Sanghvi
Viraj Sanghvi
LSLaura F. Steel
Laura F. Steel

13 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PMPrathibha Mohan
Prathibha Mohan
JPJoyce Pasion
Joyce Pasion
GCGiovanni Ciriello
Giovanni Ciriello
NLNathalie Lailler
Nathalie Lailler
ESElisa de Stanchina
Elisa de Stanchina
KSKamini Singh
Kamini Singh
The eIF4E translation initiation factor has oncogenic properties and concordantly, the inhibitory eIF4E-binding protein (4EBP1) is considered a tumor suppressor. The exact molecular effects of 4EBP1 activation in cancer are still unknown. Surprisingly, 4EBP1 is a target of genomic copy number gains (Chr. 8p11) in breast and lung cancer. We noticed that 4EBP1 gains are genetically linked to gains in neighboring genes, including WHSC1L1 and FGFR1. Our results show that FGFR1 gains act to attenuate the function of 4EBP1 via PI3K-mediated phosphorylation at Thr37/46, Ser65, and Thr70 sites. This implies that not 4EBP1 but instead FGFR1 is the genetic target of Chr. 8p11 gains in breast and lung cancer. Accordingly, these tumors show increased sensitivity to FGFR1 and PI3K inhibition, and this is a therapeutic vulnerability through restoring the tumor-suppressive function of 4EBP1. Ribosome profiling reveals genes involved in insulin signaling, glucose metabolism, and the inositol pathway to be the relevant translational targets of 4EBP1. These mRNAs are among the top 200 translation targets and are highly enriched for structure and sequence motifs in their 5′UTR, which depends on the 4EBP1-EIF4E activity. In summary, we identified the translational targets of 4EBP1-EIF4E that facilitate the tumor suppressor function of 4EBP1 in cancer.